Cathepsin C

A papain-like cysteine protease that has specificity for amino terminal dipeptides. The enzyme plays a role in the activation of several pro-inflammatory serine proteases by removal of their aminoterminal inhibitory dipeptides. Genetic mutations that cause loss of cathepsin C activity in humans are associated with PAPILLON-LEFEVRE DISEASE.

Also Known As:

Networked: 187 relevant articles (4 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Fan, Kai: 8 articles (01/2022 - 05/2012)
2.	Ma, Jianmei: 8 articles (01/2022 - 05/2012)
3.	Pham, Christine T N: 8 articles (01/2016 - 02/2002)
4.	Yang, Xiaohan: 7 articles (01/2022 - 01/2016)
5.	Korkmaz, Brice: 7 articles (01/2022 - 07/2013)
6.	Ikenaka, Kazuhiro: 6 articles (01/2022 - 01/2016)
7.	Shimizu, Takahiro: 6 articles (01/2022 - 01/2016)
8.	Zhang, Yanli: 6 articles (01/2022 - 01/2016)
9.	Jenne, Dieter E: 6 articles (12/2021 - 07/2013)
10.	Liu, Gang: 5 articles (01/2022 - 01/2018)

Related Diseases

1.	Bronchiectasis 05/01/2023 - "A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf." 08/01/2023 - "BI 1291583: a novel selective inhibitor of cathepsin C with superior in vivo profile for the treatment of bronchiectasis." 05/01/2023 - "Inhibition of cathepsin C (CatC) activity has the potential to decrease activation of neutrophil-derived serine proteases in patients with bronchiectasis, thereby reducing airway inflammation, improving symptoms, reducing exacerbations and preventing further airway damage. " 11/01/2023 - "Chymase inhibitors were given safely in Phase II trials without demonstrating benefits, whereas dipeptidyl peptidase-I inhibitor improved bronchiectasis, in effects likely related to inactivation of the enzyme in neutrophils." 12/05/2021 - "With INS1007 (trade name: brensocatib) being granted a breakthrough drug designation by FDA for the treatment of Adult Non-cystic Fibrosis Bronchiectasis and Coronavirus Disease 2019, the development of cathepsin C inhibitor will attract attentions from medicinal chemists in the future soon. "
2.	Pancreatitis 09/01/2021 - "clarkii; moreover, the upregulation of the expression level of pancreatitis-associated protein-2 and cathepsin C indicated that fenvalerate caused possible inflammatory pathological injury to P. " 11/01/2019 - "Deficiency of cathepsin C ameliorates severity of acute pancreatitis by reduction of neutrophil elastase activation and cleavage of E-cadherin."
3.	Membranous Glomerulonephritis (Membranous Nephropathy) 01/01/2020 - "IHC showed that glomerular tuft staining for cathepsin B, cathepsin C, and annexin A3 in cFSGS was significantly greater than in other FSGS variants, in minimal change disease, or in membranous nephropathy. "
4.	Toxoplasmosis 10/01/2017 - "DNA Vaccines Encoding Toxoplasma gondii Cathepsin C 1 Induce Protection against Toxoplasmosis in Mice."
5.	Lipoid Nephrosis (Glomerulonephritis, Minimal Change) 01/01/2020 - "IHC showed that glomerular tuft staining for cathepsin B, cathepsin C, and annexin A3 in cFSGS was significantly greater than in other FSGS variants, in minimal change disease, or in membranous nephropathy. "

Related Drugs and Biologics

1.	Cathepsin B
2.	Chymases (Chymase)
3.	Enzymes
4.	Leukocyte Elastase (Neutrophil Elastase)
5.	Cadherins (E-Cadherin)
6.	DNA Vaccines
7.	Annexin A3
8.	Peptide Hydrolases (Proteases)
9.	Cysteine Proteases (Cysteine Protease)
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics
2.	Lung Transplantation
3.	Premedication